Biodexa Pharmaceuticals PLC (BDRX) FinancialsBDRXBiodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (BDRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial, accounting for 111.0% of total sales, equivalent to £3.68M. Another important revenue stream is Pipeline R&D. Understanding this composition is critical for investors evaluating how BDRX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Biodexa Pharmaceuticals PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -61.77%, provide a clear picture of how effectively BDRX converts its operational activities into shareholder value.

In the context of the broader market, BDRX competes directly with industry leaders such as IDYA and LEGN. With a market capitalization of $1.56M, it holds a significant position in the sector. When comparing efficiency, BDRX's gross margin of N/A stands against IDYA's 100.00% and LEGN's 64.54%. Such benchmarking helps identify whether Biodexa Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.

Biodexa's financial performance is concerning, with a price-to-sales ratio of 11.16 and a price-to-book ratio of 0.08, indicating overvaluation relative to its book value despite low sales.